Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Emerge is the third Phase 3 study of MM120 ODT, with the Voyage and Panorama studies in GAD already underway. “In our Phase 2b study, MADRS score improvements after a single MM120 100 µg dose ...

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Camzyos--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for ...

Today, Johnson & Johnson announced promising new phase 3 data for icotrokinra (JNJ-2113), a first-in-class oral interleukin (IL)-23 receptor antagonist, showing that 75% of adolescents with ...